Survival of children with bone sarcoma in Europe since 1978

Stiller, Charles; Craft, A W; Corazziari, Isabella

doi:10.1016/s0959-8049(01)00004-1

Cited by 111 publications

(68 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results are also lower than those reported in the EUROCARE-3 study analysis, which reported 66% 5-year survival for osteosarcoma and 69% for Ewing sarcoma during the time period 1990 -1994 (Gatta et al, 2003). However, our results are in line with data from an earlier EUROCARE study, which reported 5-year survival for malignant bone tumours in children aged 0 -14 years in England and Wales to be 43 and 45% for osteosarcoma and Ewing sarcoma, respectively, for 1978-1989, and 55 and 57% for 1985-1989(Stiller et al, 2001). Poorer survival rates may be due to failure to improve accrual into trials.…”

Section: Discussionsupporting

confidence: 90%

Incidence and survival of childhood bone cancer in northern England and the West Midlands, 1981–2002

et al. 2009

View full text Add to dashboard Cite

There is a paucity of population-based studies examining incidence and survival trends in childhood bone tumours. We used high quality data from four population-based registries in England. Incidence patterns and trends were described using Poisson regression. Survival trends were analysed using Cox regression. There were 374 cases of childhood (ages 0 -14 years) bone tumours (206 osteosarcomas, 144 Ewing sarcomas, 16 chondrosarcomas, 8 other bone tumours) registered in the period 1981 -2002. Overall incidence (per million person years) rates were 2.63 (95% confidence interval (CI) 2.27 -2.99) for osteosarcoma, 1.90 (1.58 -2.21) for Ewing sarcoma and 0.21 (0.11 -0.31) for chondrosarcoma. Incidence of Ewing sarcoma declined at an average rate of 3.1% (95% CI 0.6 -5.6) per annum (P ¼ 0.04), which may be due to tumour reclassification, but there was no change in osteosarcoma incidence. Survival showed marked improvement over the 20 years (1981 -2000) for Ewing sarcoma (hazard ratio (HR) per annum ¼ 0.95 95% CI 0.91 -0.99; P ¼ 0.02). However, no improvement was seen for osteosarcoma patients (HR per annum ¼ 1.02 95% CI 0.98 -1.05; P ¼ 0.35) over this time period. Reasons for failure to improve survival including potential delays in diagnosis, accrual to trials, adherence to therapy and lack of improvement in treatment strategies all need to be considered.

show abstract

Section: Discussionsupporting

confidence: 90%

Incidence and survival of childhood bone cancer in northern England and the West Midlands, 1981–2002

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Small sample sizes are a consequence of the low incidence of these tumours and practice of treating patients for surgery in Supra-Regional Centres. Moreover, survival rates remain lower than other childhood cancers [13,14]. This reduced the number of mothers potentially available for interview at T2 and suggests that attention to physical care may seem more urgent than psychological care.…”

Section: Discussionmentioning

confidence: 99%

‘He Never Liked Sport Anyway’ ‐ Mother′s Views of Young PeopleCoping With a Bone Tumour in the Lower Limb

Earle

Eiser

Grimer

2005

Sarcoma

View full text Add to dashboard Cite

Purpose: Treatment for a bone tumour can compromise quality of life (QOL), especially for young patients. We used qualitative methods to assess mothers' views of patients' experiences and their coping strategies at approximately 6 months after diagnosis (T1: n ¼ 12) and 12-18 months later (T2: n ¼ 11). Subjects: Mothers of young people (aged 6-22 years) who were undergoing treatment for either osteosarcoma or Ewing's sarcoma in the lower limb took part. Methods: A semi-structured interview was devised to assess participation in sport, social life, schooling and general mobility. Interviews were transcribed and analysed using content analysis. Results: Mothers reported a number of situations in which QOL was compromised, and these remained relatively constant over time (mean ¼ 4.25 at T1 and 4.27 at T2). However, strategies to manage these difficulties changed from Problem (constructive attempts to deal with challenges) to Emotion (managing the situation through use of emotions) focused coping from T1 to T2. Discussion: Although the sample size is small, our results suggest that patients adopt a variety of coping strategies to deal with the physical and social restrictions associated with disease and treatment. The findings suggest that young people continue to experience many stresses up to 18 months after diagnosis. The shift from Problem to Emotion focussed coping over time may suggest a degree of acceptance of practical problems.

show abstract

“…Approximately 60% of osteosarcoma cases occur in patients aged less than 20 years (Stiller et al, 2001;Fletcher et al, 2006;Stiller et al, 2006;. In Thailand, the Thai Pediatric Oncology Group (TPOG) reported the crude annual incidence of osteosarcoma of 1.9 cases per million children (Wiangnon et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

Carboplatin and Doxorubicin in Treatment of Pediatric Osteosarcoma: A 9-year Single Institute Experience in the Northern Region of Thailand

Choeyprasert¹,

Natesirinilkul²,

Charoenkwan³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Osteosarcoma is the most common primary bone tumor in childhood and adolescence. Carboplatin, a platinum-derived agent, is used as neoadjuvant chemotherapy for pediatric osteosarcoma because of its anti-tumor activity and had low toxicity as compared to cisplatin. Objective: To determine demographic data, prognostic factors and outcome of childhood osteosarcoma treated with a carboplatin-based chemotherapeutic protocol at Chiang Mai University. Method: A retrospective analysis was conducted on 34 osteosarcoma patients aged less than 18 years and treated between 2003 and 2011. Results: Overall limb-salvage and amputation rates were 23.5% and 70.6%, respectively. With the mean follow-up time of 29.5 months (1.5-108.9), the Kaplan-Meier analysis for 3-year disease-free survival (DFS) and 3-year overall survival (OS) were 20.2±7.7% and 47.1±9.5% respectively. Patients who had initial pulmonary metastasis were at significantly greater risk for developing recurrence (p=0.02, OR=7; 1.2-40.1) and had a tendency to have lower 3-year OS compared to those without initial pulmonary metastasis (28.1±13%, 63.1±12.3%, respectively, p=0.202). On univariate analysis, age at diagnosis >14 years and patients who were declined surgery were significantly associated with lower 3-year OS (p=0.008 and <0.05, respectively). However, age at diagnosis, sex, tumor size and histological subtypes were not found to significantly affect recurrence or survival. Conclusions: In our study, the survival rate was far lower than those reported from developed countries. These might indicate the ineffectiveness of carboplatin in combination with doxorubicin as frontline treatment of pediatric osteosarcoma, especially in those with initial pulmonary metastasis. Refinement in risk and treatment stratification and dose intensification for pediatric osteosarcoma constitutes a future challenge to improve outcomes, especially in metastatic patients who may need a more intensive regimen.

show abstract

Survival of children with bone sarcoma in Europe since 1978

Cited by 111 publications

References 18 publications

Incidence and survival of childhood bone cancer in northern England and the West Midlands, 1981–2002

Incidence and survival of childhood bone cancer in northern England and the West Midlands, 1981–2002

‘He Never Liked Sport Anyway’ ‐ Mother′s Views of Young PeopleCoping With a Bone Tumour in the Lower Limb

Carboplatin and Doxorubicin in Treatment of Pediatric Osteosarcoma: A 9-year Single Institute Experience in the Northern Region of Thailand

Contact Info

Product

Resources

About